This technology provides an anti-inflammatory pharmaceutical composition and a health functional food composition for antioxidant and anti-inflammatory effects, using farnesol-containing fractions obtained by hydrolyzing Acanthopanax bark extract with Pectinex enzyme and fractionating it with ethyl acetate or water. The ethyl acetate fraction may contain caffeic acid, falcarindiol, and linoleic acid, while the water fraction may contain acanthoside B and D.
Acanthopanax stems and roots have been traditionally used for sedation, rheumatism, diabetes, gastric ulcers, and hypertension. However, research has focused on stems, leaves, and fruits, leaving the efficacy of the bark largely unknown. Furthermore, harvesting roots requires cutting down the plant, and seed propagation takes over 18 months, leading to concerns about over-harvesting and threats to wild resources.
This technology involves reflux extraction and concentration of Acanthopanax bark, followed by enzymatic hydrolysis, enzyme removal, and fractionation to produce a material with superior antioxidant and anti-inflammatory effects compared to non-hydrolyzed extracts. The fractions inhibit nitric oxide production and IL-6/TNF-α cytokine release, while scavenging DPPH radicals and superoxide. Applicable as natural anti-inflammatories for joint and musculoskeletal pain, antioxidant health supplements, and high-performance ingredients, this method utilizes under-researched bark to expand resource utility and enhance efficacy.
N/A
